亚洲患者与非亚洲患者的强效抗血栓治疗 - Suppr

Potent antithrombotic treatments in Asian vs. non-Asian patients.

作者信息

Goto Shinya, Goto Shinichi

机构信息

Department of Medicine (Cardiology), Tokai University School of Medicine, 143 Shimokasuya, Kanagawa 259-1193, Isehara, Japan.

出版信息

Eur Heart J. 2022 Oct 7;43(37):3553-3555. doi: 10.1093/eurheartj/ehac390.

DOI:10.1093/eurheartj/ehac390

PMID:35920146

Abstract

摘要

相似文献

Potent antithrombotic treatments in Asian vs. non-Asian patients.

Eur Heart J. 2022 Oct 7;43(37):3553-3555. doi: 10.1093/eurheartj/ehac390.

Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.

Eur Heart J. 2022 Oct 7;43(37):3542-3552. doi: 10.1093/eurheartj/ehac309.

Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.

Eur J Prev Cardiol. 2020 Feb;27(3):296-307. doi: 10.1177/2047487319882154. Epub 2019 Oct 15.

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.

Adv Ther. 2020 Jul;37(7):3348-3369. doi: 10.1007/s12325-020-01398-8. Epub 2020 Jun 9.

Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review.

Expert Rev Cardiovasc Ther. 2020 Dec;18(12):881-889. doi: 10.1080/14779072.2020.1833719. Epub 2020 Oct 14.

External applicability of the COMPASS trial: the Western Denmark Heart Registry.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):192-199. doi: 10.1093/ehjcvp/pvz013.

Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.

Crit Pathw Cardiol. 2018 Jun;17(2):53-68. doi: 10.1097/HPC.0000000000000149.

Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.

Circ Res. 2019 Feb;124(3):416-425. doi: 10.1161/CIRCRESAHA.118.313141.

Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.

J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104936. doi: 10.1016/j.jstrokecerebrovasdis.2020.104936. Epub 2020 Jun 8.

Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.

Cardiovasc Res. 2021 Feb 22;117(3):942-949. doi: 10.1093/cvr/cvaa100.

引用本文的文献

Regional Heterogeneity in the Risk of Thrombosis and Bleeding in Patients With Peripheral Artery Disease.

JACC Asia. 2025 May 7;5(6):755-7. doi: 10.1016/j.jacasi.2025.03.007.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Potent antithrombotic treatments in Asian vs. non-Asian patients.

作者信息

Goto Shinya, Goto Shinichi

机构信息

Department of Medicine (Cardiology), Tokai University School of Medicine, 143 Shimokasuya, Kanagawa 259-1193, Isehara, Japan.

出版信息

Eur Heart J. 2022 Oct 7;43(37):3553-3555. doi: 10.1093/eurheartj/ehac390.

DOI:10.1093/eurheartj/ehac390

PMID:35920146

Abstract

摘要

相似文献

Potent antithrombotic treatments in Asian vs. non-Asian patients.

Eur Heart J. 2022 Oct 7;43(37):3553-3555. doi: 10.1093/eurheartj/ehac390.

Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial.

Eur Heart J. 2022 Oct 7;43(37):3542-3552. doi: 10.1093/eurheartj/ehac309.

Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.

Eur J Prev Cardiol. 2020 Feb;27(3):296-307. doi: 10.1177/2047487319882154. Epub 2019 Oct 15.

Cost-Effectiveness of Coronary and Peripheral Artery Disease Antithrombotic Treatments in Finland.

Adv Ther. 2020 Jul;37(7):3348-3369. doi: 10.1007/s12325-020-01398-8. Epub 2020 Jun 9.

Antithrombotic strategies for patients with coronary and lower extremity peripheral artery diseases: a narrative review.

Expert Rev Cardiovasc Ther. 2020 Dec;18(12):881-889. doi: 10.1080/14779072.2020.1833719. Epub 2020 Oct 14.

External applicability of the COMPASS trial: the Western Denmark Heart Registry.

Eur Heart J Cardiovasc Pharmacother. 2019 Oct 1;5(4):192-199. doi: 10.1093/ehjcvp/pvz013.

Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.

Crit Pathw Cardiol. 2018 Jun;17(2):53-68. doi: 10.1097/HPC.0000000000000149.

Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.

Circ Res. 2019 Feb;124(3):416-425. doi: 10.1161/CIRCRESAHA.118.313141.

Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.

J Stroke Cerebrovasc Dis. 2020 Aug;29(8):104936. doi: 10.1016/j.jstrokecerebrovasdis.2020.104936. Epub 2020 Jun 8.

Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.

Cardiovasc Res. 2021 Feb 22;117(3):942-949. doi: 10.1093/cvr/cvaa100.

引用本文的文献

Regional Heterogeneity in the Risk of Thrombosis and Bleeding in Patients With Peripheral Artery Disease.

JACC Asia. 2025 May 7;5(6):755-7. doi: 10.1016/j.jacasi.2025.03.007.

Potent antithrombotic treatments in Asian vs. non-Asian patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Potent antithrombotic treatments in Asian vs. non-Asian patients.

作者信息

机构信息

出版信息

相似文献

引用本文的文献